STATE OF WISCONSIN DEPARTMENT OF ADMINISTRATION DOA-2049 (R03/2012) DIVISION OF EXECUTIVE BUDGET AND FINANCE 101 EAST WILSON STREET, 10TH FLOOR P.O. BOX 7864 MADISON, WI 53707-7864 FAX: (608) 267-0372

ADMINISTRATIVE RULES Fiscal Estimate & Economic Impact Analysis

Type of Estimate and Analysis Original □ Updated □ Corrected		
2. Administrative Rule Chapter, Title and Number CSB 2.48		
3. Subject Scheduling eluxadoline		
4. Fund Sources Affected ☐ GPR ☐ FED ☐ PRO ☐ PRS ☐ SEG ☐ SEG-S	5. Chapter 20, Stats. Appropriations Affected $20.165(1)(g)$	
6. Fiscal Effect of Implementing the Rule ☑ No Fiscal Effect ☐ Increase Existing Revenues ☐ Indeterminate ☐ Decrease Existing Revenues	☐ Increase Costs ☐ Could Absorb Within Agency's Budget ☐ Decrease Cost	
7. The Rule Will Impact the Following (Check All That Apply) State's Economy Local Government Units Specific Businesses/Sectors Public Utility Rate Payers Small Businesses (if checked, complete Attachment A)		
8. Would Implementation and Compliance Costs Be Greater Than \$20 million? ☐ Yes ☐ No		
9. Policy Problem Addressed bythe Rule The United States Department of Justice, Drug Enforcement Administration scheduled eluxadoline as a schedule IV controlled substance effective November 12, 2015. The Wisconsin Controlled Substances Board took affirmative action on November 15, 2016 to similarly treat eluxadoline as a schedule IV controlled substance effective November 21, 2016. The Board is currently promulgating a final rule.		
10. Summaryof the businesses, business sectors, associations representing business, local governmental units, and individuals that may be affected by the proposed rule that were contacted for comments. This rule was posted for economic comments and none were received.		
11. Identify the local governmental units that participated in the development of this EIA. None		
12. Summary of Rule's Economic and Fiscal Impact on Specific Businesses, Business Sectors, Public Utility Rate Payers, Local Governmental Units and the State's Economy as a Whole (Include Implementation and Compliance Costs Expected to be Incurred) This rule will not have a fiscal or economic impact.		
13. Benefits of Implementing the Rule and Alternative(s) to Implementing the Rule The benefit is for the federal and state controlled substances acts to be in conformity and alleviate confusion. In addition, it is in the best interest of Wisconsin citizens to schedule eluxadoline as controlled substances.		
14. Long Range Implications of Implementing the Rule Eluxadoline will be treated as a schedule IV controlled subs	tance.	
15. Compare With Approaches Being Used by Federal Government The federal government has scheduled eluxadoline as a schedule IV controlled substance.		
16. Compare With Approaches Being Used by Neighboring States Minnesota has scheduled eluxadoline as a schedule IV controlled substance. Illinois a	olled substance. Iowa is in the process of scheduling	

STATE OF WISCONSIN DEPARTMENT OF ADMINISTRATION DOA-2049 (R03/2012) DIVISION OF EXECUTIVE BUDGET AND FINANCE 101 EAST WILSON STREET, 10TH FLOOR P.O. BOX 7864 MADISON, WI 53707-7864 FAX: (608) 267-0372

ADMINISTRATIVE RULES Fiscal Estimate & Economic Impact Analysis

17. Contact Name	18. Contact Phone Number
Sharon Henes	(608) 261-2377

This document can be made available in alternate formats to individuals with disabilities upon request.

STATE OF WISCONSIN DEPARTMENT OF ADMINISTRATION DOA-2049 (R03/2012) DIVISION OF EXECUTIVE BUDGET AND FINANCE 101 EAST WILSON STREET, 10TH FLOOR P.O. BOX 7864 MADISON, WI 53707-7864 FAX: (608) 267-0372

ADMINISTRATIVE RULES Fiscal Estimate & Economic Impact Analysis

ATTACHMENT A

 Summary of Rule's Economic and Fiscal Impact on Small Businesses (Separately for each Small Business Sector, Include Implementation and Compliance Costs Expected to be Incurred)
2. Summary of the data sources used to measure the Rule's impact on Small Businesses
3. Did the agency consider the following methods to reduce the impact of the Rule on Small Businesses?
☐ Less Stringent Compliance or Reporting Requirements
☐ Less Stringent Schedules or Deadlines for Compliance or Reporting
☐ Consolidation or Simplification of Reporting Requirements
☐ Establishment of performance standards in lieu of Design or Operational Standards
☐ Exemption of Small Businesses from some or all requirements
☐ Other, describe:
4. Describe the methods incorporated into the Rule that will reduce its impact on Small Businesses
5. Describe the Rule's Enforcement Provisions
6. Did the Agency prepare a Cost Benefit Analysis (if Yes, attach to form)
☐ Yes ☐ No